Connection

Co-Authors

This is a "connection" page, showing publications co-authored by JASON B FLEMING and RONALD A DEPINHO.
Connection Strength

0.405
  1. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature. 2017 02 02; 542(7639):119-123.
    View in: PubMed
    Score: 0.146
  2. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. J Clin Invest. 2022 12 15; 132(24).
    View in: PubMed
    Score: 0.055
  3. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019 04; 568(7752):410-414.
    View in: PubMed
    Score: 0.042
  4. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017 02 16; 542(7641):362-366.
    View in: PubMed
    Score: 0.037
  5. In?Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep. 2016 06 28; 16(1):133-147.
    View in: PubMed
    Score: 0.035
  6. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res. 2015 Mar 15; 75(6):1091-101.
    View in: PubMed
    Score: 0.032
  7. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014 Oct 30; 514(7524):628-32.
    View in: PubMed
    Score: 0.031
  8. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013 Apr 04; 496(7443):101-5.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.